title: Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
abstract: BACKGROUND
  This single-arm, phase II study was designed to determine the efficacy and safety of panobinostat and bortezomib in patients with advanced pancreatic cancer.
  
  
  METHODS
  Patients had to have a histological diagnosis of pancreatic cancer and progression on a standard gemcitabine-based therapy. Treatment cycles consisted of 21 days, with bortezomib given twice weekly at 1.3 mg/m(2) and panobinostat three times weekly at 20 mg during the first two weeks, followed by a 9-day rest period.
  
  
  RESULTS
  Seven patients (3 female, 4 male) were treated with at least one cycle, but the study was suspended after the enrollment of these patients because of a complete lack of treatment responses and early treatment-related toxicity. Median progression-free survival was 2.1 months (95% Confidence interval: 1.7-2.3 months). The most common grade 3 or 4 adverse events were thrombocytopenia (57%) and diarrhea (29%).
  
  
  CONCLUSIONS
  Treatment of advanced pancreatic cancer with bortezomib in combination with panobinostat is not supported by our clinical study.
authors.affiliation: Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA.
authors.forename: Hengbing
authors.initials: H
authors.lastname: Wang
authors.forename: Qing
authors.initials: Q
authors.lastname: Cao
authors.forename: Arkadiusz Z
authors.initials: AZ
authors.lastname: Dudek
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage; D007211:Indoles; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D000077767:Panobinostat; D011719:Pyrazines / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D001897:Boronic Acids; D006877:Hydroxamic Acids; D007211:Indoles; D011719:Pyrazines; D003841:Deoxycytidine; D000069286:Bortezomib; D000077767:Panobinostat; D000093542:Gemcitabine